Lastly, fenofibrate treatment lowered VLDL-apoB concentrations and secretion rates in NAFLD patients, consistent with our data showing suppressed LDL-apoB ASR with concurrent fenofibrate and ACCi treatment (Fig. 3B, (40)). The gene discussed is APOB; the disease is metabolic dysfunction-associated steatotic liver disease.